Literature DB >> 17566770

Cell therapy in models for temporal lobe epilepsy.

R Raedt1, A Van Dycke, K Vonck, P Boon.   

Abstract

For patients with refractory epilepsy it is important to search for alternative treatments. One of these potential treatments could be introducing new cells or modulating endogenous neurogenesis to reconstruct damaged epileptic circuits or to bring neurotransmitter function back into balance. In this review the scientific basis of these cell therapy strategies is discussed and the results are critically evaluated. Research on cell transplantation strategies has mainly been performed in animal models for temporal lobe epilepsy, in which seizure foci or seizure propagation pathways are targeted. Promising results have been obtained, although there remains a lot of debate about the relevance of the animal models, the appropriate target for transplantation, the suitable cell source and the proper time point for transplantation. From the presented studies it should be evident that transplanted cells can survive and sometimes even integrate in an epileptic brain and in a brain that is subjected to epileptogenic interventions. There is evidence that transplanted cells can partially restore damaged structures and/or release substances that modulate existent or induced hyperexcitability. Even though several studies show encouraging results, more studies need to be done in animal models with spontaneous seizures in order to have a better comparison to the human situation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17566770     DOI: 10.1016/j.seizure.2007.05.003

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  19 in total

Review 1.  Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies.

Authors:  Detlev Boison
Journal:  Epilepsy Res       Date:  2009-05-09       Impact factor: 3.045

2.  Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis.

Authors:  Tianfu Li; Gaoying Ren; David L Kaplan; Detlev Boison
Journal:  Epilepsy Res       Date:  2009-02-12       Impact factor: 3.045

3.  Astrocytes derived from fetal neural progenitor cells as a novel source for therapeutic adenosine delivery.

Authors:  Annelies Van Dycke; Robrecht Raedt; Alain Verstraete; Panos Theofilas; Wytse Wadman; Kristl Vonck; Detlev Boison; Paul Boon
Journal:  Seizure       Date:  2010-06-17       Impact factor: 3.184

Review 4.  Recent advancements in stem cell and gene therapies for neurological disorders and intractable epilepsy.

Authors:  Janice R Naegele; Xu Maisano; Jia Yang; Sara Royston; Efrain Ribeiro
Journal:  Neuropharmacology       Date:  2010-02-08       Impact factor: 5.250

5.  Silk polymer-based adenosine release: therapeutic potential for epilepsy.

Authors:  Andrew Wilz; Eleanor M Pritchard; Tianfu Li; Jing-Quan Lan; David L Kaplan; Detlev Boison
Journal:  Biomaterials       Date:  2008-06-02       Impact factor: 12.479

6.  Benefits and risks of intranigral transplantation of GABA-producing cells subsequent to the establishment of kindling-induced seizures.

Authors:  Marc W Nolte; Wolfgang Löscher; Christiane Herden; William J Freed; Manuela Gernert
Journal:  Neurobiol Dis       Date:  2008-07-15       Impact factor: 5.996

7.  Adenosine dysfunction in astrogliosis: cause for seizure generation?

Authors:  Tianfu Li; Jing Quan Lan; Bertil B Fredholm; Roger P Simon; Detlev Boison
Journal:  Neuron Glia Biol       Date:  2007-11

Review 8.  Adenosine-associated delivery systems.

Authors:  Mehdi Kazemzadeh-Narbat; Nasim Annabi; Ali Tamayol; Rahmi Oklu; Amyl Ghanem; Ali Khademhosseini
Journal:  J Drug Target       Date:  2015       Impact factor: 5.121

Review 9.  A Molecular Approach to Epilepsy Management: from Current Therapeutic Methods to Preconditioning Efforts.

Authors:  Elham Amini; Mohsen Rezaei; Norlinah Mohamed Ibrahim; Mojtaba Golpich; Rasoul Ghasemi; Zahurin Mohamed; Azman Ali Raymond; Leila Dargahi; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2014-09-09       Impact factor: 5.590

Review 10.  Engineered adenosine-releasing cells for epilepsy therapy: human mesenchymal stem cells and human embryonic stem cells.

Authors:  Detlev Boison
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.